Free Trial
NASDAQ:RXST

RxSight 5/7/2025 Earnings Report

RxSight logo
$14.61 +0.05 (+0.34%)
As of 10:02 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

RxSight EPS Results

Actual EPS
N/A
Consensus EPS
-$0.03
Beat/Miss
N/A
One Year Ago EPS
N/A

RxSight Revenue Results

Actual Revenue
N/A
Expected Revenue
$38.74 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

RxSight Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

RxSight Earnings Headlines

Brokerages Set RxSight, Inc. (NASDAQ:RXST) Price Target at $37.60
#1 AI play of the decade…? (The answer will shock you)
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
RxSight initiated with a Neutral at Piper Sandler
RxSight downgraded to Neutral from Buy at UBS
UBS Downgrades RxSight (RXST)
See More RxSight Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RxSight? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RxSight and other key companies, straight to your email.

About RxSight

RxSight (NASDAQ:RXST), a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

View RxSight Profile

More Earnings Resources from MarketBeat